Neratinib in Combination With Ruxolitinib in Patients With mTNBC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neratinib in Combination With Ruxolitinib in Patients With mTNBC — Stella

Recruiting

Back to Metastatic Triple-Negative Breast Carcinoma trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

United States

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas

Key details

Phase

Very early testing

Sponsor

Baylor Research Institute

Enrollment target

~20 participants

Started

September 2024

Primary completion

June 2026

Age range

18 Years and older

Sex

Female only

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov